How have AGY shares performed in 2024?

Allergy Therapeutics' stock was trading at GBX 2.50 at the beginning of 2024. Since then, AGY shares have increased by 6.0% and is now trading at GBX 2.65. View the best growth stocks for 2024 here .

How were Allergy Therapeutics' earnings last quarter?

Allergy Therapeutics plc (LON:AGY) issued its quarterly earnings results on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter. Allergy Therapeutics had a negative trailing twelve-month return on equity of 216.27% and a negative net margin of 72.28%.

What other stocks do shareholders of Allergy Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include (RLYP) (RLYP) , Royalty Pharma (RPRX) , Verastem (VSTM) , Berkeley Energia (BKY) , Burford Capital (BUR) , Direxion Daily Gold Miners Index Bear 2x Shares (DUST) , Flowtech Fluidpower (FLO) , Merrimack Pharmaceuticals (MACK) and Shanta Gold (SHG) .

How do I buy shares of Allergy Therapeutics?

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:AGY

Allergy Therapeutics (AGY) Share Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free AGY Stock Alerts

GBX 2.65

-0.20 (-7.02%)

(As of 04/19/2024 ET)

Compare

Today's Range: 2.65
▼
2.85
50-Day Range: 2.40
▼
3
52-Week Range: 0.80
▼
3.90

Volume: 1.43 million shs
Average Volume: 797,267 shs
Market Capitalization: £126.41 million

P/E Ratio: N/A
Dividend Yield: 8.33%
Price Target: N/A

Stock Analysis Chart Competitors Headlines

Get Allergy Therapeutics alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Allergy Therapeutics Stock (LON:AGY)

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

AGY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AGY Stock News Headlines

April 18, 2024 | dailymail.co.uk

The most common 'inhalant' allergies

March 29, 2024 | finance.yahoo.com

Allergy Therapeutics First Half 2024 Earnings: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023)

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

March 28, 2024 | lse.co.uk

AIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenue

March 2, 2024 | finance.yahoo.com

Allergy Therapeutics plc (AGY.L)

November 8, 2023 | morningstar.com

Allergy Therapeutics PLC AGY

November 6, 2023 | marketwatch.com

Allergy Therapeutics Extends Cash Runway to End of Year

October 14, 2023 | finance.yahoo.com

Allergy Therapeutics (LON:AGY) dips 10.0% this week as increasing losses might not be inspiring confidence among its investors

April 20, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

October 13, 2023 | marketwatch.com

Allergy Therapeutics to Raise GBP40.75 Mln; Mandatory Cash Offer Triggered

July 31, 2023 | abcnews.go.com

Red meat allergy caused by ticks is an 'emerging public health concern': CDC

June 22, 2023 | forbes.com

What Is A Mold Allergy? Symptoms, Causes And Treatments

June 19, 2023 | marketwatch.com

Allergy Therapeutics Shares Fall on Going Concern Uncertainty

June 14, 2023 | technews.tmcnet.com

Generational Equity Advises Allergy, Sinus & Asthma Family Health Center in its Sale to AllerVie Health

June 12, 2023 | msn.com

Intellia Therapeutics stock gains on CRISPR treatment results

June 12, 2023 | msn.com

Why Intellia Therapeutics Stock Is Rising Monday

June 9, 2023 | proactiveinvestors.com

Allergy Therapeutics to present key scientific findings from its research portfolio

May 26, 2023 | benzinga.com

Global Allergy Immunotherapies Market Report 2023: Growing Consumer Awareness Towards Health Benefits of Allergy Immunotherapies Fuels the Sector

May 9, 2023 | marketwatch.com

Global Food Allergy Diagnostics And Therapeutics Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast 2030

May 5, 2023 | marketwatch.com

Peanut Allergy Therapeutics Market Projected to Reach Significant Growth Value by 2030

April 19, 2023 | proactiveinvestors.com

Allergy Therapeutics peanut vaccine candidate negotiates its early clinical hurdle

April 11, 2023 | finance.yahoo.com

Form 8.3 - The Allergy Therapeutics Plc

April 7, 2023 | forbes.com

Nasal Spray For Allergies: What You Need To Know

March 29, 2023 | usatoday.com

Spring is here—here’s what you need to survive seasonal allergies

March 29, 2023 | marketwatch.com

Global Mugwort Pollen and Allergies Therapeutics Drug Market : Latest Report 2029

March 28, 2023 | marketwatch.com

2023 Allergy Treatment Market: Best Practices of Top Players and Business Success Plans till 2030

March 28, 2023 | marketwatch.com

Allergy Diagnostics And Therapeutics Market by 2031

See More Headlines

Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/04/2020
Today: 4/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: LON
Sector: Medical
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Current Symbol: LON:AGY
CUSIP: N/A
CIK: N/A
Web: www.allergytherapeutics.com
Phone: +44-1903-844700
Fax: N/A
Employees: 612
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): GBX (0.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: -30.7
Net Income: £-43,070,000.00
Net Margins: -72.28%
Pretax Margin: N/A
Return on Equity: -216.27%
Return on Assets: -31.48%

Debt

Debt-to-Equity Ratio: 1,741.96
Current Ratio: 1.81
Quick Ratio: 1.48

Sales & Book Value

Annual Sales: £59.59 million
Price / Sales: 2.12
Cash Flow: GBX 0.72 per share
Price / Cash Flow: 3.66
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 4,770,000,000
Free Float: N/A
Market Cap: £126.41 million
Optionable: Not Optionable
Beta: 1.31

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Manuel Llobet (Age 59)
CEO & Executive Director
Comp: $411.98k
Mr. Shaun Antony Furlong (Age 48)
CFO & Executive Director
Ms. Beverly Lees
Group Operations Director
Simon Piggott
Head of Clinical Science
Alan Bullimore
Head of Communication & Market Development
Karley Charlotte Mouatt Cheesman
Company Secretary
Mr. Matthew Heath
Principal Scientist

Key Competitors

View All Competitors

Insiders

Zheqing Shen
Bought 247,935,056 shares on 11/9/2023
Total: £247.94 M ($1.00/share)

AGY Stock Analysis - Frequently Asked Questions

How have AGY shares performed in 2024?: Allergy Therapeutics' stock was trading at GBX 2.50 at the beginning of 2024. Since then, AGY shares have increased by 6.0% and is now trading at GBX 2.65.
View the best growth stocks for 2024 here.
How were Allergy Therapeutics' earnings last quarter?: Allergy Therapeutics plc (LON:AGY) issued its quarterly earnings results on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter. Allergy Therapeutics had a negative trailing twelve-month return on equity of 216.27% and a negative net margin of 72.28%.
What other stocks do shareholders of Allergy Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR), Direxion Daily Gold Miners Index Bear 2x Shares (DUST), Flowtech Fluidpower (FLO), Merrimack Pharmaceuticals (MACK) and Shanta Gold (SHG).
How do I buy shares of Allergy Therapeutics?: Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:AGY) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial